Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Lenalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention. Browse Lenalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Therapy scope
Lenalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Lenalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 445–456 of 703 matching trials for Lenalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00772915
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT02538965
View directory record Official record
Conditions
Leukemia, Myeloid
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

NCT01732861
View directory record Official record
Conditions
Leukemia Lymphocytic Chronic B-Cell
Interventions
CC-292, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Huntsville, Alabama • Lafayette, Indiana • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT01629082
View directory record Official record
Conditions
Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, Bone Marrow Diseases, Neutropenia, Acute Myeloid Leukemia (AML)
Interventions
Clofarabine, Lenalidomide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

NCT01133275
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
Prednisone, Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

NCT00581919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bort, Dex, and Dox with ALCAR
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
5
States / cities
Janesville, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

NCT00840931
View directory record Official record
Conditions
Leukemia
Interventions
lenalidomide, bystander vaccine
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

NCT00974233
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Bendamustine, Rituximab, Lenalidomide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
10
States / cities
Green Bay, Wisconsin • Janesville, Wisconsin • La Crosse, Wisconsin + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

NCT00655668
View directory record Official record
Conditions
T-cell Non-Hodgkin's Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Beverly Hills, California • Wichita, Kansas • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

NCT00975806
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenalidomide, Sunitinib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 30, 2026, 12:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, Etoposide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Burbank, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 30, 2026, 12:34 AM EDT

About this Lenalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Lenalidomide.